Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest To Review Role In Desmoteplase Program Following DIAS-2 Failure

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Development of Forest/Paion's clot dissolving protein desmoteplase for the treatment of acute ischemic stroke could be in question after a Phase III study failed to show an efficacy benefit in patients treated with the drug versus placebo

You may also be interested in...



Forest/PAION Desmoteplase Scare Is Brief: Trial Resumes After Two-Day Hold

A pre-Halloween scare for PAION/Forest's vampire bat protein-based stroke therapy desmoteplase resolved quickly when a halt on patient recruitment in a Phase IIb/III trial was lifted within two days of the announcement of a possible safety signal

Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.

Fewer US Market Access Restrictions For Branded I&I Drugs Will Drive Growth

Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.

UsernamePublicRestriction

Register

PS003586

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel